Target binding in tumor dominates that in plasma, with greater affinities (IC50 of 0.025 μM for HER2, and 0.029 μM for EGFR) that effectively extract albumin-bound lapatinib from blood passing through the tumor. This evidence concerns the gene ERBB2 and neoplasm.